The systems announced the Dana-Farber Beth Israel Deaconess Cancer Collaboration Sept. 14. Under the agreement, the proposed adult cancer hospital will operate under the license of Dana-Farber while each organization remains fully independent.
The hospital will have 300 beds and measure at approximately 688,100 square feet, according to a legal notice obtained by the Business Journal. It will be constructed in Boston’s Longwood Medical Area and connect to Dana-Farber’s existing facility. Dana-Farber plans to relocate 30 inpatient beds from a space that it currently shares with Brigham and Women’s Hospital.
Dana-Farber Cancer Institute and Brigham and Women’s Hospital have been clinically affiliated since 1997 and their current agreement runs through 2028.
A specific timeline of the Dana-Farber-BIDMC cancer partnership and the changes it entails was not provided in the announcement, although the systems said they anticipate “several years” of planning to finalize the operational model, obtain regulatory approvals and construct the inpatient hospital.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
